Advances in therapies for lung adenocarcinoma have arisen from advances in biomarker testing. The biomarker testing landscape is evolving quickly, as is its impact on patient care, and pathologists need to keep up current on the field, explains Jeff Chang, MD, FCAP, in this CAPcast interview. Dr. Chang recently wrote an article on this topic for the Precision Medicine section of CAP.org (https://capatholo.gy/3jQmPVS). Dr. Chang is a member of the CAP’s Personalized Healthcare Committee, as well as the Associate Editor of the Archives of Pathology & Laboratory Medicine.